ShinJJHamadEMurthySet al.Heart failure in women. Clin Cardiol2012; 35: 172–177.
2.
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med1987; 316: 1429–1435.
3.
BardyGHLeeKLMarkDBet al.Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med2005; 352: 225–237.
4.
CohnJNJohnsonGZiescheSet al.A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med1991; 325: 303–310.
5.
GoldenbergIKutyifaVKleinHUet al.Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med2014; 370: 1694–1701.
6.
McMurrayJJPackerMDesaiASet al.Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med2014; 371: 993–1004.
7.
PackerMBristowMRCohnJNet al.The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med1996; 334: 1349–1355.
8.
PackerMCoatsAJFowlerMBet al.Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med2001; 344: 1651–1658.
9.
PittBZannadFRemmeWJet al.for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med1999; 341: 709–717.
10.
YusufSPittBDavisCEet al.Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med1991; 325: 293–302.
11.
YusufSPittBDavisCEet al.Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med1992; 327: 685–691.
12.
ZannadFMcMurrayJJKrumHet al.Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med2011; 364: 11–21.
13.
AgostoniPCorraUCattadoriGet al.Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis. Int J Cardiol2013; 167: 2710–2718.
14.
CherubiniADel SignoreSOuslanderJet al.Fighting against age discrimination in clinical trials. J Am Geriatr Soc2010; 58: 1791–1796.
15.
HeiatAGrossCPKrumholzHM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med2002; 162: 1682–1688.
16.
RosanoGMLewisBAgewallSet al.Gender differences in the effect of cardiovascular drugs: A position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J2015; 36: 2677–2680.
17.
NairBR. Evidence based medicine for older people: available, accessible, acceptable, adaptable?Australas J Ageing2002; 21: 58–60.
18.
MosterdAHoesAW. Clinical epidemiology of heart failure. Heart2007; 93: 1137–1146.
19.
CeiaFFonsecaCMotaTet al.Prevalence of chronic heart failure in Southwestern Europe: The EPICA study. Eur J Heart Fail2002; 4: 531–539.
20.
Van RietEEHoesAWWagenaarKPet al.Epidemiology of heart failure: The prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail2016; 18: 242–252.
21.
Van DeursenVMUrsoRLarocheCet al.Co-morbidities in patients with heart failure: An analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail2014; 16: 103–111.
22.
KhatibRMcKeeMShannonHet al.Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: An analysis of the PURE study data. Lancet2016; 387: 61–69.
23.
HelisEAugustincicLSteinerSet al.Time trends in cardiovascular and all-cause mortality in the ‘old’ and ‘new’ European Union countries. Eur J Cardiovasc Prev Rehabil2011; 18: 347–359.
24.
GronhojMHGerkeOMickleyHet al.External validity of a cardiovascular screening including a coronary artery calcium examination in middle-aged individuals from the general population. Eur J Prev Cardiol.2018; 25: 1156–1166.
